SCHEMBL3033016

SCHEMBL3033016

CCCOC(=O)c1cccc(CC)c1

nearest known ligand 0.66

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.66
ALDH1A1 P00352 4/20 0.57
CYP4F2 P78329 2/20 0.55
CYP4A11 Q02928 2/20 0.55
TSHR P16473 2/20 0.54
ESR1 P03372 1/20 0.54
CHRM1 P11229 1/20 0.54
SLC6A2 P23975 1/20 0.54
KDR P35968 1/20 0.54
TDP1 Q9NUW8 1/20 0.54
KDM4E B2RXH2 1/20 0.53
POLB P06746 1/20 0.53
MAPT P10636 1/20 0.51
KMT2A Q03164 1/20 0.51
LOXL2 Q9Y4K0 1/20 0.50
SLC7A5 Q01650 1/20 0.50
JMJD6 Q6NYC1 1/20 0.48
MEP1B Q16820 1/20 0.48
HPGD P15428 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13291593 0.93 CYP4F2 (0.62) LMNAALDH1A1CYP4F2CYP4A11TSHR
SCHEMBL27425790 0.92 LMNA (0.57) LMNAALDH1A1CYP4F2CYP4A11TSHR
SCHEMBL7464858 0.91 LMNA (0.55) LMNAALDH1A1CYP4F2CYP4A11TSHR
SCHEMBL10706157 0.90 L3MBTL1 (0.57) LMNAALDH1A1CYP4F2CYP4A11TSHR
SCHEMBL15344632 0.90 LMNA (0.62) LMNAALDH1A1CYP4F2CYP4A11TSHR
SCHEMBL111664 0.89 LMNA (0.75) LMNAALDH1A1TSHRESR1CHRM1
SCHEMBL31346674 0.89 LMNA (0.60) LMNAALDH1A1CYP4F2CYP4A11TSHR
SCHEMBL11599440 0.89 LMNA (0.60) LMNAALDH1A1CYP4F2CYP4A11TSHR
SCHEMBL6527211 0.89 LMNA (0.60) LMNAALDH1A1CYP4F2CYP4A11TSHR
SCHEMBL3813671 0.89 LMNA (0.60) LMNAALDH1A1CYP4F2CYP4A11TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8569195-B2 Internal and external donor compounds for olefin polymerization catalysts II BASF CORPORATION (US) 2013-10-29 US claimed
CN-114315728-A Imidazole ionic liquid and application thereof in alcoholysis polymerization of 2, 5-furandicarboxylic acid ester 中国科学院大连化学物理研究所 2022-04-12 CN disclosed
CN-105622423-B A kind of adduct of magnesium halides and its preparation method and application 中国石油化工股份有限公司 2019-06-28 CN disclosed
CN-105622793-B For the catalytic component and catalyst system of olefinic polymerization and its application and olefine polymerizing process 中国石油化工股份有限公司 2019-05-31 CN disclosed
CN-105541877-B Adduct of magnesium halides and application and the catalytic component for olefinic polymerization and catalyst system and application and olefine polymerizing process 中国石油化工股份有限公司 2019-03-22 CN disclosed
CN-105622644-B A kind of adduct of magnesium halides and its application 中国石油化工股份有限公司 2018-12-28 CN disclosed
CN-105622794-B For the catalytic component and catalyst system of olefinic polymerization and its application and olefine polymerizing process 中国石油化工股份有限公司 2018-07-20 CN disclosed
EP-2782938-B1 HIGH ACTIVITY CATALYST FOR OLEFIN POLYMERIZATION BASF CORP (US) 2016-08-31 EP disclosed
EP-1957073-B1 MEDICINAL DRUG OTSUKA PHARMA CO LTD (JP) 2014-04-23 EP disclosed
EP-2612858-A1 STAT3/5 activation inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-07-10 EP disclosed
US-8263599-B2 STAT3/5 activation inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-09-11 US disclosed
US-8236826-B2 Diarylether derivatives as antitumor agents OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-08-07 US disclosed
US-8188277-B2 Aromatic compounds for suppressing the generation of collagen OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-05-29 US disclosed
US-20100210661-A1 STAT3/5 ACTIVATION INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-19 US disclosed
US-20100004438-A1 DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-01-07 US disclosed
EP-1957073-A2 MEDICINAL DRUG OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-08-20 EP disclosed
US-20070270422-A1 Aromatic Compounds OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-11-22 US disclosed
WO-2007066784-A2 DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-06-14 WO disclosed
EP-1773797-A2 AROMATIC COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-04-18 EP disclosed
WO-2006014012-A2 AROMATIC COMPOUNDS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210661-A1 STAT3/5 ACTIVATION INHIBITOR STAT3, JAK2, STAT1 LMNA 4683/4885ALDH1A1 1814/4885CYP4F2 2635/4885
US-20100004438-A1 DIARYLETHER DERIVATIVES AS ANTITUMOR AGENTS ROS1, CBR1, CBR3 LMNA 4340/4885ALDH1A1 265/4885CYP4F2 2279/4885
US-20070270422-A1 Aromatic Compounds COL1A1, COL2A1, COL14A1 LMNA 1091/4885ALDH1A1 475/4885CYP4F2 435/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.